Skip to main content
LQDA
NASDAQ Life Sciences

Director Stephen Bloch unloads $17.8M in Liquidia stock as insider distribution wave continues

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$86.22
Mkt Cap
$7.667B
52W Low
$16.82
52W High
$91.1
52W Position info
413% above low
Off High info
5.4% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $16.82.

Summary

Liquidia Corp director Stephen Bloch sold $17.8 million in stock on July 22-23, continuing a 90-day trend of heavy insider selling with no offsetting purchases.


Key Events · Ownership and Investor Activity · LQDA

  • Director Sells $17.8M in Stock

    Stephen Bloch sold 200,000 shares at prices between $87.70 and $90.71 on July 22-23, 2026, for total proceeds of $17,786,409. The shares were held indirectly through Canaan VIII L.P.

  • Part of Broader Insider Selling Wave

    This sale contributes to a 90-day net insider selling total of $144.7 million across 13 insiders, with zero open-market purchases, signaling a persistent distribution trend.

  • Post-Sale Holdings Remain Substantial

    After the sales, Bloch still holds 664,071 shares indirectly and 71,594 shares directly, indicating continued but reduced exposure.


Analysis · LQDA · Life Sciences

Director Stephen Bloch sold $17.8 million of Liquidia Corp stock over two days, adding to a wave of insider selling that has seen over $144 million in open-market sales in the past 90 days with zero insider purchases. While Bloch is not a C-suite executive and the shares were held indirectly through Canaan VIII L.P., the sale is part of a persistent distribution pattern that raises questions about insider confidence despite the company's recent strong earnings and S&P SmallCap 600 inclusion.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $86.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7B. The 52-week trading range was $16.82 to $91.10. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.45
Real-time Price: $56.63 info
Change: +$9.18 (+19%) info
Market Cap: $5.103B info
LQDA
Nov 10, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $47.40
Real-time Price: $56.63 info
Change: +$9.23 (+19%) info
Market Cap: $5.103B info
LQDA
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.00
Real-time Price: $56.63 info
Change: +$6.63 (+13%) info
Market Cap: $5.103B info
LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $56.63 info
Change: +$17.13 (+43%) info
Market Cap: $5.103B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $56.63 info
Change: +$24.87 (+78%) info
Market Cap: $5.103B info